Effects of p38MAPK‑mediated excision repair cross‑complementation 1 expression on prognosis of patients with non‑small cell lung cancer

He,Dan; Ma,Xiaomei; Wu,Zhenhua; Wang,Yang; Zhao,Shuyuan; Han,Feng; Sun,Wei

doi:10.3892/ol.2017.6649

Effects of p38MAPK‑mediated excision repair cross‑complementation 1 expression on prognosis of patients with non‑small cell lung cancer

Authors:
- Dan He
- Xiaomei Ma
- Zhenhua Wu
- Yang Wang
- Shuyuan Zhao
- Feng Han
- Wei Sun
View Affiliations

Affiliations: Department of Thoracic Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China, Department of Pathology, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China
Published online on: July 21, 2017 https://doi.org/10.3892/ol.2017.6649
Pages: 3463-3472
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of excision repair cross-complementation 1 (ERCC1) expression on the prognosis of patients with non‑small cell lung cancer (NSCLC). A total of 140 patients with NSCLC who underwent radical resection were included. Immunohistochemical staining was performed on the tissue specimens obtained from patients and correlation analysis was used to determine the association between ERCC1 expression and clinicopathological characteristics. Cell proliferation was assessed using an MTT assay. The mRNA and protein expression levels were detected using reverse transcription‑quantitative polymerase chain reaction and western blot analysis, respectively. The expression of ERCC1 was demonstrated to be significantly elevated in tumor tissue compared with adjacent tissue samples. Furthermore, the expression of ERCC1 in squamous carcinoma was significantly higher compared with in adenocarcinoma samples. The expression of ERCC1 in patients who smoke was significantly higher compared with in the non‑smokers. The 3‑year disease‑free survival (DFS) and overall survival (OS) for ERCC1‑negative patients were higher compared with ERCC1‑positive patients. Multivariate analysis demonstrated that ERCC1 expression, pathological staging, and tumor staging were important prognostic factors for NSCLC. Subgroup analysis revealed that the 3‑year OS rate for ERCC1‑negative patients with stage II‑III tumors who received systematic adjuvant chemotherapy was higher compared with ERCC1‑negative patients. The 3‑year DFS and OS rates for ERCC1‑negative patients with squamous carcinoma were higher compared with ERCC1‑positive patients. In addition, p38 inhibitor treatment significantly inhibited the mRNA and protein expression levels of ERCC1 in A549 cells, and enhanced the sensitivity of cells to cisplatin. The results of the present study suggest that ERCC1 expression is an important prognostic indicator for NSCLC, particularly for patients with stage II‑III tumors who receive systematic platinum‑based adjuvant chemotherapy.

View Figures

View References

1	Le Chevalier T: Adjuvant chemotherapy for resectable non-small-cell lung cancer: Where is it going? Ann Oncol. 7:(Suppl 7). vii196–vii198. 2010.
2	He YW, Zhao ML, Yang XY, Zeng J, Deng QH and He JX: Prognostic value of ERCC1, RRM1 and TS proteins in patients with resected non-small cell lung cancer. Cancer Chemother Pharmacol. 75:861–867. 2015. View Article : Google Scholar : PubMed/NCBI
3	Geredeli C, Artac M, Yildirim S, Inal A, Dede I, Guler T, Boruban MC, Koral L, Karaagac M, Zamani AG, et al: Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer. Tumour Biol. 36:4279–4285. 2015. View Article : Google Scholar : PubMed/NCBI
4	Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker R, Jiang C, et al: Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous carcinoma but not adenocarcinoma: Theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol. 23:2245–2252. 2012. View Article : Google Scholar : PubMed/NCBI
5	Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ, et al: A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer. 120:2343–2351. 2014. View Article : Google Scholar : PubMed/NCBI
6	Kalikaki A, Voutsina A, Koutsopoulos A, Papadaki C, Sfakianaki M, Yachnakis E, Xyrafas A, Kotsakis A, Agelaki S, Souglakos J, et al: ERCC1 SNPs as potential predictive biomarkers in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Invest. 33:107–113. 2015. View Article : Google Scholar : PubMed/NCBI
7	Sad LM, Younis SG and Elity MM: Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer. Med Oncol. 31:582014. View Article : Google Scholar : PubMed/NCBI
8	Sullivan I, Salazar J, Majem M, Pallarés C, Del Río E, Páez D, Baiget M and Barnadas A: Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett. 353:160–166. 2014. View Article : Google Scholar : PubMed/NCBI
9	Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V and Souglakos J: ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol. 7:663–671. 2012. View Article : Google Scholar : PubMed/NCBI
10	Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. J Clin Oncol. 25:2747–2754. 2007. View Article : Google Scholar : PubMed/NCBI
11	Roth JA and Carlson JJ: Prognostic role of ERCC1 in advanced non-small-cell lung cancer: A systematic review and meta-analysis. Clin Lung Cancer. 12:393–401. 2011. View Article : Google Scholar : PubMed/NCBI
12	Li CF, Cao S and Meng SD: Tumor dormancy and identification of therapeutic targets. Ai Zheng. 28:555–558. 2009.(In Chinese). PubMed/NCBI
13	Paillas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C, et al: Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res. 71:1041–1049. 2011. View Article : Google Scholar : PubMed/NCBI
14	Wen J, Cheng HY, Feng Y, Rice L, Liu S, Mo A, Huang J, Zu Y, Ballon DJ and Chang CC: P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol. 140:169–180. 2008. View Article : Google Scholar : PubMed/NCBI
15	Ranganathan AC, Adam AP, Zhang L and Aguirre-Ghiso JA: Tumor cell dormancy induced by p38SAPK and ER-stress signaling: An adaptive advantage for metastatic cells? Cancer Biol Ther. 5:729–735. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ranganathan AC, Zhang L, Adam AP and Aguirre-Ghiso JA: Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 66:1702–1711. 2006. View Article : Google Scholar : PubMed/NCBI
17	He D, Zhao XQ, Chen XG, Fang Y, Singh S, Talele TT, Qiu HJ, Liang YJ, Wang XK, Zhang GQ, et al: BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells. PLoS One. 8:e541812013. View Article : Google Scholar : PubMed/NCBI
18	Hubner RA, Riley RD, Billingham LJ and Popat S: Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: A meta-analysis of published studies and recommendations. PLoS One. 6:e251642011. View Article : Google Scholar : PubMed/NCBI
19	Planchard D, Domont J, Taranchon E, Monnet I, Tredaniel J, Caliandro R, Validire P, Besse B, Soria JC and Fouret P: The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Ann Oncol. 20:1257–1263. 2009. View Article : Google Scholar : PubMed/NCBI
20	Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, Ambudkar SV, et al: Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res. 71:3029–3041. 2011. View Article : Google Scholar : PubMed/NCBI
21	Planchard D, Camara-Clayette V, Dorvault N, Soria JC and Fouret P: p38 mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients. Cancer. 118:5015–5025. 2012. View Article : Google Scholar : PubMed/NCBI
22	Seetharam RN, Sood A, Basu-Mallick A, Augenlicht LH, Mariadason JM and Goel S: Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. Anticancer Res. 30:2531–2538. 2010.PubMed/NCBI
23	Ueda S, Shirabe K, Morita K, Umeda K, Kayashima H, Uchiyama H, Soejima Y, Taketomi A and Maehara Y: Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma. Ann Surg Oncol. 18:1204–1211. 2011. View Article : Google Scholar : PubMed/NCBI
24	Liu GY, Qu QX, Mi RR and Qi J: Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer. Zhonghua Zhong Liu Za Zhi. 30:184–187. 2008.(In Chinese). PubMed/NCBI
25	Cheong HT, Hui CW, Xu F, Mok TSK and Wong CH: Abstract 2558: The mechanistic study on the effect of platinum-based chemotherapy efficacy imposed by EGFR-TKI regulated ERCC1 in non-small cell lung cancer (NSCLC). Cancer Res. 75:25582015. View Article : Google Scholar
26	Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
27	Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK and Spitz MR: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A molecular epidemiologic study. J Natl Cancer Inst. 92:1764–1772. 2000. View Article : Google Scholar : PubMed/NCBI
28	Marwick JA, Kirkham PA, Stevenson CS, Danahay H, Giddings J, Butler K, Donaldson K, Macnee W and Rahman I: Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol. 31:633–642. 2004. View Article : Google Scholar : PubMed/NCBI
29	Yao H, Edirisinghe I, Rajendrasozhan S, Yang SR, Caito S, Adenuga D and Rahman I: Cigarette smoke-mediated inflammatory and oxidative responses are strain-dependent in mice. Am J Physiol Lung Cell Mol Physiol. 294:L1174–L1186. 2008. View Article : Google Scholar : PubMed/NCBI
30	Zhong CY, Zhou YM, Douglas GC, Witschi H and Pinkerton KE: MAPK/AP-1 signal pathway in tobacco smoke-induced cell proliferation and squamous metaplasia in the lungs of rats. Carcinogenesis. 26:2187–2195. 2005. View Article : Google Scholar : PubMed/NCBI
31	Bolton SJ, Pinnion K, Oreffo V, Foster M and Pinkerton KE: Characterisation of the proximal airway squamous metaplasia induced by chronic tobacco smoke exposure in spontaneously hypertensive rats. Respir Res. 10:1182009. View Article : Google Scholar : PubMed/NCBI